EICHOR
● Terminated
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
Condition: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Sponsor: Amgen
About this study
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) and nivolumab. The main objective Part 2 is to compare efficacy of bemarituzumab plus chemotherapy (mFOLFOX6 or capecitabine combined with oxaliplatin (CAPOX)) and nivolumab to placebo plus chemotherapy (mFOLFOX6 or CAPOX) and nivolumab as assessed by overall survival.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (348)
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | — |
| The Oncology Institute Clinical Research | Cerritos, California, United States | — |
| Cancer and Blood Specialty Clinic | Downey, California, United States | — |
| City of Hope National Medical Center | Duarte, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
| University of California Irvine | Orange, California, United States | — |
| Torrance Memorial Physician Network | Redondo Beach, California, United States | — |
| Translational Research in Oncology - US Inc | Santa Monica, California, United States | — |
| Translational Research in Oncology US Inc, Trio Central Pharmacy | Santa Monica, California, United States | — |
| Olive View-University of California in Los Angeles Medical Center | Sylmar, California, United States | — |
| Presbyterian Intercommunity Hospital Health Whitter Hospital | Whittier, California, United States | — |
| Yale New Haven Hospital Yale Cancer Center | New Haven, Connecticut, United States | — |
+ 336 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05111626